The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study
Background: We previously reported that antofloxacin-based bismuth quadruple therapy was safe and effective for Helicobacter pylori ( H. pylori ) eradication. It is not clear whether the addition of Saccharomyces boulardii ( S. boulardii ) to antofloxacin-based quadruple therapy can improve the erad...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848221147763 |
| _version_ | 1811159519676334080 |
|---|---|
| author | Xiao-Jian He Xiao-Ling Wang Dong-Jie Sun Xiao-Yan Huang Gang Liu Da-Zhou Li Hai-Lan Lin Xiang-Peng Zeng Dong-Liang Li Wen Wang |
| author_facet | Xiao-Jian He Xiao-Ling Wang Dong-Jie Sun Xiao-Yan Huang Gang Liu Da-Zhou Li Hai-Lan Lin Xiang-Peng Zeng Dong-Liang Li Wen Wang |
| author_sort | Xiao-Jian He |
| collection | DOAJ |
| description | Background: We previously reported that antofloxacin-based bismuth quadruple therapy was safe and effective for Helicobacter pylori ( H. pylori ) eradication. It is not clear whether the addition of Saccharomyces boulardii ( S. boulardii ) to antofloxacin-based quadruple therapy can improve the eradication rate of H. pylori and reduce adverse events. Objective: To investigate the effect of adding S. boulardii to antofloxacin-based quadruple therapy on the eradication rate of H. pylori and the adverse events. Design: Single-center, prospective randomized controlled study. Methods: A total of 172 patients with H. pylori infection were randomly assigned to the test and control groups. Patients in the control group ( n = 86) received antofloxacin-based bismuth quadruple therapy for 14 days. On this basis, cases in the test group ( n = 86) received S. boulardii 500 mg b.i.d. The eradication rate of H. pylori and adverse events were observed 4 weeks after the treatment. Results: There were no statistically significant differences in the eradication rates of H. pylori and frequency of diarrhea between the test group and control group ( p > 0.05). The duration of diarrhea in the test group was significantly shorter than in the control group ( p < 0.001). In addition, the two groups exhibited similar adverse event rates for epigastric pain, abdominal distention, dizzy, vomiting, and rash ( p > 0.05). The severity of adverse reactions was similar between the two groups ( p > 0.05), and most of them had mild adverse events. Conclusion: Although the addition of S. boulardii to antofloxacin-based quadruple therapy could not improve the eradication rate of H. pylori , it could shorten the time of antibiotic-associated diarrhea and reduce the incidence of diarrhea. Trial registration number: ChiCTR2200056931. |
| first_indexed | 2024-04-10T05:42:35Z |
| format | Article |
| id | doaj.art-d594d30734a147849e32c80d5ace13a3 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-04-10T05:42:35Z |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-d594d30734a147849e32c80d5ace13a32023-03-06T07:33:09ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482023-01-011610.1177/17562848221147763The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control studyXiao-Jian HeXiao-Ling WangDong-Jie SunXiao-Yan HuangGang LiuDa-Zhou LiHai-Lan LinXiang-Peng ZengDong-Liang LiWen WangBackground: We previously reported that antofloxacin-based bismuth quadruple therapy was safe and effective for Helicobacter pylori ( H. pylori ) eradication. It is not clear whether the addition of Saccharomyces boulardii ( S. boulardii ) to antofloxacin-based quadruple therapy can improve the eradication rate of H. pylori and reduce adverse events. Objective: To investigate the effect of adding S. boulardii to antofloxacin-based quadruple therapy on the eradication rate of H. pylori and the adverse events. Design: Single-center, prospective randomized controlled study. Methods: A total of 172 patients with H. pylori infection were randomly assigned to the test and control groups. Patients in the control group ( n = 86) received antofloxacin-based bismuth quadruple therapy for 14 days. On this basis, cases in the test group ( n = 86) received S. boulardii 500 mg b.i.d. The eradication rate of H. pylori and adverse events were observed 4 weeks after the treatment. Results: There were no statistically significant differences in the eradication rates of H. pylori and frequency of diarrhea between the test group and control group ( p > 0.05). The duration of diarrhea in the test group was significantly shorter than in the control group ( p < 0.001). In addition, the two groups exhibited similar adverse event rates for epigastric pain, abdominal distention, dizzy, vomiting, and rash ( p > 0.05). The severity of adverse reactions was similar between the two groups ( p > 0.05), and most of them had mild adverse events. Conclusion: Although the addition of S. boulardii to antofloxacin-based quadruple therapy could not improve the eradication rate of H. pylori , it could shorten the time of antibiotic-associated diarrhea and reduce the incidence of diarrhea. Trial registration number: ChiCTR2200056931.https://doi.org/10.1177/17562848221147763 |
| spellingShingle | Xiao-Jian He Xiao-Ling Wang Dong-Jie Sun Xiao-Yan Huang Gang Liu Da-Zhou Li Hai-Lan Lin Xiang-Peng Zeng Dong-Liang Li Wen Wang The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study Therapeutic Advances in Gastroenterology |
| title | The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study |
| title_full | The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study |
| title_fullStr | The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study |
| title_full_unstemmed | The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study |
| title_short | The efficacy and safety of in addition to antofloxacin-based bismuth quadruple therapy for eradication: a single-center, prospective randomized-control study |
| title_sort | efficacy and safety of in addition to antofloxacin based bismuth quadruple therapy for eradication a single center prospective randomized control study |
| url | https://doi.org/10.1177/17562848221147763 |
| work_keys_str_mv | AT xiaojianhe theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiaolingwang theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dongjiesun theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiaoyanhuang theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT gangliu theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dazhouli theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT hailanlin theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiangpengzeng theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dongliangli theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT wenwang theefficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiaojianhe efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiaolingwang efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dongjiesun efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiaoyanhuang efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT gangliu efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dazhouli efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT hailanlin efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT xiangpengzeng efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT dongliangli efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy AT wenwang efficacyandsafetyofinadditiontoantofloxacinbasedbismuthquadrupletherapyforeradicationasinglecenterprospectiverandomizedcontrolstudy |